The parenteral injectables market is rapidly growing and expected to reach $150.65 billion by 2028. This growth is driven by the expanding biopharmaceuticals industry – in which biologics are increasingly being used to treat chronic conditions like arthritis and diabetes – as well as the billions of messenger ribonucleic acid (mRNA) inoculations that continue to be delivered globally. This growth is putting pressure on biologics CDMOs to expand their capacity and explore more efficient ways to speed up production while also providing a shorter path to market.
The greater focus on patient-centric treatment is evolving the services that manufacturing partners need to offer, shifting the emphasis on contemporary drug design from simply preserving basic quality attributes – such as safety, efficacy, and potency in a simple container – to more complex formulations that preserve the value of the drug while providing additional benefits, including precise easy-to-administer delivery systems for better dose compliance. This focus on innovations in injectable devices requires CDMOs to advance their drug delivery capabilities to meet patient needs and expectations. Explore the barriers facing manufacturers and how to best evaluate a drug substance's characteristics and determine the most appropriate delivery device.